**QCDR Measure:**

AAO-22: Giant Cell Arteritis: Absence of fellow eye involvement after corticosteroid treatment

**National Quality Strategy Domain:**

Effective Clinical Care

**Measure Type:**

Outcome

**Description:**

Percentage of patients without fellow eye involvement 1-26 weeks after initiating corticosteroids in patients with unilateral visual loss.

**Instructions:**

This measure is to be reported a minimum of once per reporting period for patients diagnosed with giant cell arteritis between January 1 and June 30. It is anticipated that clinicians who provide the primary management of patients with giant cell arteritis will submit this measure.

**Denominator:**

All patients aged 18 years or older diagnosed with giant cell arteritis between January 1 and June 30 with unilateral vision loss.

**Denominator Criteria**

Patients aged ≥ 18 years

AND

Two or more encounters within the last 6 months (CPT: 99201, 99202, 99203, 99204, 99205, 99244, 99245, 92002, 92004, 92012, 92014, 99212, 99213, 99214, 99215)

AND

Diagnosis of giant cell arteritis

- Giant cell arteritis with polymyalgia rheumatica (ICD-10: M31.5)
- Other giant cell arteritis (ICD-10: M31.6)

AND

Unilateral vision loss from optic nerve or retinal ischemia
• Ischemic optic neuropathy (ICD-10: H47.011, H47.012)
• Central retinal artery occlusion (ICD-10: H34.11, H34.12)
• Other retinal artery occlusion (ICD-10: H34.211, H34.212, H34.231, H34.232)

AND

Patient receiving corticosteroid treatment

Numerator:
Patients without fellow eye involvement 1-26 weeks after initiating corticosteroid treatment.

Numerator Options:
Performance Met: Patients without fellow eye involvement 1 week to 26 weeks after initiating corticosteroid treatment.
Performance Not Met: Patients with fellow eye involvement 1 week to 26 weeks after initiating corticosteroid treatment.

Improvement Notation:
Higher score indicates better performance